Jiangsu Recbio Technology Co., Ltd. (2179.HK)
| Previous close | 7.890 |
| Open | 9.070 |
| Bid | 0.000 x N/A |
| Ask | 9.050 x N/A |
| Day's range | 9.070 - 9.070 |
| 52-week range | 7.890 - 14.200 |
| Volume | |
| Avg. volume | 11,194 |
| Market cap | 4.371B |
| Beta (5Y monthly) | -0.14 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.310 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 12.98 |
PR NewswireRecbio And Rongsheng Biotech Signed a Strategic Cooperation Agreement On The New Adjuvant Vaccine Project
Jiangsu Recbio Technology Co., Ltd. (hereafter referred to as Recbio; stock code: 02179.HK) and Shanghai Rongsheng Biotech Co.,Ltd.(hereafter referred to as "Rongsheng Biotech") successfully held a signing and project launch meeting for new adjuvant vaccine research and development project in Shanghai. At the meeting, the two parties signed a strategic cooperation agreement on the new adjuvant vaccine project and discussed in depth the details of project advancement.
PR NewswireJiangsu Recbio Technology Co., Ltd. announced 2023 annual results report and latest progress
Innovative vaccine company Recbio (02179.HK) announced its latest progress and annual results for 2023. The company always adhered to the mission of " Protect Human Health With Best-In-Class Vaccines", and achieved the following milestones and progress in research pipeline and business operations.
PR NewswirePositive Results In The Interim Analysis Of The Clinical Trial Of Recbio's Novel Adjuvanted Recombinant Shingles Vaccine REC610 In The Philippines
Jiangsu Recbio Technology Co., Ltd. (the "Company", together with its subsidiaries, the "Group") is pleased to announce that the novel adjuvanted recombinant shingles vaccine REC610 independently developed by the Company has recently achieved positive results in the interim analysis of first-in-human ("FIH") clinical trial in the Philippines.
